Morcamilast

Morcamilast (ME3183) is a selective and orally active PDE4 inhibitor, with IC50s of 1.28 nM (PDE4A1A), 2.33 nM (PDE4B1), and 1.63 nM (PDE4D2) respectively. Morcamilast shows weak inhibition of PDEs other than PDE4s Morcamilast is an anti-inflammatory agent and inhibits LPS (HY-D1056) -induced release of TNF-α, IL-12/23p40, IL-23, and IL-17A in human PBMCs and T cells. Morcamilast has antipruritic effect and can be used in the study of psoriasis, atopic dermatitis, and other inflammatory diseases[1][2].

Product Specifications

CAS Number

[2231329-25-0]

Product Name Alternative

ME3183; PDE4-IN-14

UNSPSC

12352005

Target

Interleukin Related; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pde4-in-14.html

Purity

98.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC(F)(C(C)(C)O)OC1=C(N=C(O2)N3CC4CC(C3)N4)C2=C(C=C1)C5=NC=CS5

Molecular Formula

C19H20F2N4O3S

Molecular Weight

422.45

References & Citations

[1]Ko KUMURA, et al. Crystal of benzoxazole derivative. Patent CA3104829A1.|[2]Kubota-Ishida N, et al. ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study. Eur J Pharmacol. 2024 Jan 5;962:176202.